Incyte
Incyte Corporation is an American biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company operates mainly in the hematology, oncology, and inflammation and autoimmunity therapeutic areas. Its primary commercial product is ruxolitinib, marketed under the trade names Jakafi and Opzelura for myelofibrosis and dermatological conditions. Revenue is driven predominantly by product sales of its key therapeutic drugs alongside royalty streams and licensing milestones from global partners. Incyte maintains a strong market position in target-specific oncology and small molecule inhibitor research. The company is headquartered in Wilmington, Delaware, and is listed on the Nasdaq Global Select Market.
43 of the funds FundTelligence covers report a position in Incyte.
- Legal name
- Incyte Corp
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 43
Funds holding Incyte
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 3.2 % (partially disclosed portfolio, September 2026)
- Fondsfinans Global Helse — Fondsfinans · 2.73 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 1.56 % (full portfolio disclosed, October 2026)
- HealthInvest Sustainable Healthcare — HealthInvest · 1.5 % (partially disclosed portfolio, September 2026)
- BNP Responsible US Multi-Factor Equity — BNP Paribas · 1.44 % (full portfolio disclosed, June 2026)
- Schroder ISF Healthcare Innovation — Schroders · 0.89 % (full portfolio disclosed, June 2026)
- KLP AksjeGlobal Flerfaktor — KLP · 0.49 % (full portfolio disclosed, June 2026)
- BlackRock iShares MSCI World Health Care Sector ESG UCITS ETF — BlackRock · 0.44 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 43 funds holding it.